Beschreibung:
<jats:sec><jats:title>Background</jats:title><jats:p>Leadless endocardial left ventricular (LV) pacing resynchronization therapy is a novel solution for patients with heart failure (HF) in whom conventional cardiac resynchronization therapy (CRT) failed.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>PubMed and the Cochrane Library were searched for relevant cohort studies. Clinical outcomes of interest such as ejection fraction (EF), QRS duration (QRSd), and left ventricular end-systolic volume (LVESV) were extracted and analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Five studies involving 175 HF patients for WiSE CRT were included, and patients were followed-up for 6 months. The implanted success rate ranged from 76.5 to 100%. WiSE CRT resulted in significantly narrower QRSd [mean difference (MD): −38.21 ms, 95% confidence interval (CI): −44.36 to −32.07, <jats:italic>p</jats:italic> &lt; 0.001], improved left ventricular ejection fraction (MD: 6.07%, 95% CI: 4.43 to 7.71, I<jats:sup>2</jats:sup> = 0%, <jats:italic>p</jats:italic> &lt; 0.001), reduced left ventricular end-systolic volume (MD: −23.47 ml, 95% CI: −37.18 to −9.13, <jats:italic>p</jats:italic> &lt; 0.001), and reduced left ventricular end-diastolic volume (MD: −24.02 ml, 95% CI: −37.01 to −11.03, <jats:italic>p</jats:italic> = 0.02).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Evidence from current studies suggests that leadless endocardial LV pacing resynchronization is effective for HF patients who failed conventional CRT or needed a device upgrade, and it may be an interesting rescue therapy.</jats:p></jats:sec>